Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a significant increase in short interest in July. As of July 15th, there was short interest totaling 429,660 shares, an increase of 213.0% from the June 30th total of 137,273 shares. Based on an average daily trading volume, of 7,541,738 shares, the short-interest ratio is currently 0.1 days. Approximately 77.1% of the company’s stock are sold short.

Shuttle Pharmaceuticals Price Performance

SHPH opened at $2.89 on Monday. Shuttle Pharmaceuticals has a 52 week low of $2.71 and a 52 week high of $55.90. The business’s 50 day moving average is $4.20 and its two-hundred day moving average is $9.03. The firm has a market cap of $1.85 million, a price-to-earnings ratio of -0.06 and a beta of 0.29.

Insiders Place Their Bets

In other Shuttle Pharmaceuticals news, major shareholder Financial Lp Hrt purchased 8,266 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was bought at an average cost of $3.38 per share, with a total value of $27,939.08. Following the acquisition, the insider directly owned 60,540 shares of the company’s stock, valued at approximately $204,625.20. This represents a 15.81% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders acquired 53,398 shares of company stock valued at $181,764 and sold 38,133 shares valued at $132,128. 12.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Connective Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals in the 3rd quarter valued at $357,000. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals during the 4th quarter worth $124,000. Boothbay Fund Management LLC purchased a new position in Shuttle Pharmaceuticals during the 4th quarter worth $37,000. Finally, Geode Capital Management LLC acquired a new position in Shuttle Pharmaceuticals in the fourth quarter valued at $26,000. 4.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on SHPH shares. Weiss Ratings lowered Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Friday, July 17th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Shuttle Pharmaceuticals currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .